Cargando…
The 2EF Antibody Targets a Unique N-Terminal Epitope of Trop-2 and Enhances the In Vivo Activity of the Cancer-Selective 2G10 Antibody
SIMPLE SUMMARY: We sought recognition of Trop-2 within difficult-to-reach, densely packed tumor sites. The 2EF mAb was developed, and demonstrated efficient access to Trop-2 at cell–cell junctions in breast cancer cells in culture and in prostate tumors that were not accessible to benchmark anti-Tro...
Autores principales: | Guerra, Emanuela, Trerotola, Marco, Relli, Valeria, Lattanzio, Rossano, Ceci, Martina, Boujnah, Khouloud, Pantalone, Ludovica, Di Pietro, Roberta, Iezzi, Manuela, Tinari, Nicola, Alberti, Saverio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378344/ https://www.ncbi.nlm.nih.gov/pubmed/37509383 http://dx.doi.org/10.3390/cancers15143721 |
Ejemplares similares
-
Trop‐2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis
por: Trerotola, Marco, et al.
Publicado: (2021) -
Trop-2 Is a Determinant of Breast Cancer Survival
por: Ambrogi, Federico, et al.
Publicado: (2014) -
Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer
por: Guerra, Emanuela, et al.
Publicado: (2021) -
The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises
por: Guerra, Emanuela, et al.
Publicado: (2022) -
Distinct lung cancer subtypes associate to distinct drivers of tumor progression
por: Relli, Valeria, et al.
Publicado: (2018)